{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T04:44:07Z","timestamp":1649047447374},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T00:00:00Z","timestamp":1336867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s00120-012-2875-9","type":"journal-article","created":{"date-parts":[[2012,5,11]],"date-time":"2012-05-11T11:59:47Z","timestamp":1336737587000},"page":"1209-1219","source":"Crossref","is-referenced-by-count":0,"title":["Das Harnblasenkarzinomrezidiv nach BCG-Instillationstherapie"],"prefix":"10.1007","volume":"51","author":[{"given":"J.M.","family":"Laturnus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Jocham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sommerauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,13]]},"reference":[{"key":"2875_CR1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","volume":"59","author":"Babjuk","year":"2011","unstructured":"Babjuk M, Oosterlinck W, Sylvester R et al (2011) EAU-Guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997\u20131008","journal-title":"Eur Urol"},{"key":"2875_CR2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"Sylvester","year":"2006","unstructured":"Sylvester RJ, Meijden APM van der, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466\u2013477","journal-title":"Eur Urol"},{"key":"2875_CR3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m P-U, Sylvester RJ, Crawford DE et al (2009) An individual patient data meta-analysis of the long \u2013term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56:247\u2013256","journal-title":"Eur Urol"},{"key":"2875_CR4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","volume":"63","author":"B\u00f6hle","year":"2004","unstructured":"B\u00f6hle A, Bock PR (2004) Intravesical bacille Calmette-Guerin versus Mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63:682\u2013686","journal-title":"Urology"},{"key":"2875_CR5","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","unstructured":"Sylvester RJ, Brausi MA, Kirkels WJ et al (2010) EORTC Genito-Urinary Tract Cancer Group. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57:766\u2013773","journal-title":"Eur Urol"},{"key":"2875_CR6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2011.03.051","volume":"60","author":"Herr","year":"2011","unstructured":"Herr H, Dalbagni G, Sherri MD (2011) Bacillus Calmette-Guerin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. Eur Urol 60:32\u201336","journal-title":"Eur Urol"},{"key":"2875_CR7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","volume":"177","author":"Raj","year":"2007","unstructured":"Raj GV, Herr H, Serio AM et al (2007) Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177:1283\u20131286","journal-title":"J Urol"},{"key":"2875_CR8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00345-009-0402-4","volume":"27","author":"Hautmann","year":"2009","unstructured":"Hautmann RE, Volkmer BG, Gust K (2009) Quantification of the survival benefit of early versus deferred cystectomie in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol 27:347\u2013351","journal-title":"World J Urol"},{"key":"2875_CR9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2007.06912.x","volume":"100","author":"Lambert","year":"2007","unstructured":"Lambert EH, Pierorazio PM, Poon S et al (2007) The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int 100:33\u201336","journal-title":"BJU Int"},{"key":"2875_CR10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-5347(17)34865-6","volume":"151","author":"Ameling","year":"1994","unstructured":"Ameling CL, Thrasher JB, Frazier HA et al (1994) Radical cystectomie for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151:31","journal-title":"J Urol"},{"key":"2875_CR11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","volume":"45","author":"Schrier","year":"2004","unstructured":"Schrier BP, Hollander MP, Witjes JA et al (2004) Prognosis of muscel-invasiv bladder cancer: difference between primary and progressive tumors and implications for therapy. Eur Urol 45:292\u2013296","journal-title":"Eur Urol"},{"key":"2875_CR12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","volume":"60","author":"Sven","year":"2011","unstructured":"Sven van den Bosch, Alfred Witjes J (2011) Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumor progression: a systematic review. Eur Urol 60:493\u2013500","journal-title":"Eur Urol"},{"key":"2875_CR13","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2010.11.038","volume":"59","author":"Oosterlinck","year":"2011","unstructured":"Oosterlinck W, Kirkali Z, Sylvester R et al (2011) Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmmette-Guerin and bacillus Calmette-Guerine alone in Patients with carcinoma in situ of the urinary bladder: results of an EORTC phase 2 trial. Eur Urol 59:438\u2013446","journal-title":"Eur Urol"},{"key":"2875_CR14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"Lamm","year":"2000","unstructured":"Lamm DK, Blumenstein BA, Crissman JD et al (2000) Maintenance BCG immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124\u20131129","journal-title":"J Urol"},{"key":"2875_CR15","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","volume":"49","author":"Witjes","year":"2006","unstructured":"Witjes JA (2006) Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49:790\u2013797","journal-title":"Eur Urol"},{"key":"2875_CR16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","volume":"60","author":"Fernandez-Gomez","year":"2011","unstructured":"Fernandez-Gomez J, Madero R, Solsona E et al (2011) The EORTC Tables overestimate the risk of recurrence and Progression in Patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: External validation of the EORTC risk tables. Eur Urol 60:423\u2013430","journal-title":"Eur Urol"},{"key":"2875_CR17","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","volume":"169","author":"Herr","year":"2003","unstructured":"Herr HW, Dalbagni G (2003) Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 169:1706\u20131708","journal-title":"J Urol"},{"key":"2875_CR18","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1100\/tsw.2011.30","volume":"11","author":"Lightfoot","year":"2011","unstructured":"Lightfoot AJ, Rosevear HM, O\u2018Donnell MA (2011) Recognition and treatment of BCG failure in bladder cancer. Scientific World J 11:602\u2013613","journal-title":"Scientific World J"},{"key":"2875_CR19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1442-2042.2010.02678.x","volume":"18","author":"Sylvester","year":"2011","unstructured":"Sylvester RJ (2011) Bacillus Calmette-Guerin treatment of non-muscle invasive bladder cancer. Int J Urol 18:113\u2013120","journal-title":"Int J Urol"},{"key":"2875_CR20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1586\/era.09.35","volume":"9","author":"Martin","year":"2009","unstructured":"Martin FM, Kamat AM (2009) Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev Anticancer Ther 9(6):815\u2013820","journal-title":"Expert Rev Anticancer Ther"},{"key":"2875_CR21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","volume":"66","author":"Nieder","year":"2006","unstructured":"Nieder AM, Brausi M, Lamm D et al (2006) Managment of stage T1 tumor of the bladder: International consensus panel. Urol 66:108\u2013125","journal-title":"Urol"},{"key":"2875_CR22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00345-011-0681-4","volume":"29","author":"Yates","year":"2011","unstructured":"Yates DR, Roupret M (2011) Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy. World J Urol 29:415\u2013422","journal-title":"World J Urol"},{"key":"2875_CR23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.5489\/cuaj.1196","volume":"3","author":"Zlotta","year":"2009","unstructured":"Zlotta AR, Fleshner NE, Jewett M (2009) The managment of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 3:199\u2013205","journal-title":"Can Urol Assoc J"},{"key":"2875_CR24","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","volume":"164","author":"Solsona","year":"2000","unstructured":"Solsona E, Iborra I, Almenar S et al (2000) The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164:685\u2013689","journal-title":"J Urol"},{"key":"2875_CR25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2005.04.013","volume":"48","author":"Orsola","year":"2005","unstructured":"Orsola A, Trias I, Raventos CX et al (2005) Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a\/b\/c) in BCG-treated and BCG-non-treated patients. Eur Urol 48:231\u2013238","journal-title":"Eur Urol"},{"key":"2875_CR26","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","volume":"172","author":"O","year":"2004","unstructured":"O\u2018Donnell MA, Lilli K, Leopold C (2004) Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172:888\u2013893","journal-title":"J Urol"},{"key":"2875_CR27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0022-5347(18)35074-2","volume":"173","author":"Myami","year":"2000","unstructured":"Myami JL, O\u2018Donnell MA (2000) Factors affecting response to BCG plus interferon \u03b1 patients with urothelial CIS. J Urol 173(Suppl):248","journal-title":"J Urol"},{"key":"2875_CR28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","volume":"24","author":"Joudin","year":"2006","unstructured":"Joudin FN, Smith BJ, O\u2018Donnell MA (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon Alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24:344\u2013348","journal-title":"Urol Oncol"},{"key":"2875_CR29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","volume":"71","author":"Gallagher","year":"2008","unstructured":"Gallagher BL, Joudi FN, Maymi JL, O\u2018Donnell MA (2008) Impact of previous bacillus Calmette-Guerin plus interferon intravesical therapy. Urology 71:297\u2013301","journal-title":"Urology"},{"key":"2875_CR30","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.juro.2011.04.073","volume":"186","author":"Rosevear","year":"2011","unstructured":"Rosevear HM, Lightfoot AJ, O\u2018Donnell MA et al (2011) Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma in situ. J Urol 186:817\u2013823","journal-title":"J Urol"},{"key":"2875_CR31","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","volume":"24","author":"Dalbagni","year":"2006","unstructured":"Dalbagni G, Herr HW, Bajorin D et al (2006) Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refrakory transitional cell carzinoma of the bladder. J Clin Oncol 24:2729\u20132734","journal-title":"J Clin Oncol"},{"key":"2875_CR32","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","volume":"66","author":"Bartoletti","year":"2005","unstructured":"Bartoletti R, Cai T, Sisani M et al (2005) Intrvesical gemcitabine therapy for superfivial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 66:726\u2013731","journal-title":"Urology"},{"key":"2875_CR33","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","volume":"116","author":"Di","year":"2010","unstructured":"Di Lorenzo G, Perdona S, Autorino R et al (2010) Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 116:1893\u20131900","journal-title":"Cancer"},{"key":"2875_CR34","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","volume":"24","author":"Mc","year":"2006","unstructured":"Mc Kiernan JM, Masson P, Benson MC et al (2006) Phase I trial of intravesical docetaxel in the managment of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24:3075\u20133080","journal-title":"J Clin Oncol"},{"key":"2875_CR35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2009.06.112","volume":"75","author":"Laudano","year":"2010","unstructured":"Laudano MA, Barlow LJ, Mc Kiernan JM et al (2010) Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the managment of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology 75:134\u2013137","journal-title":"Urology"},{"key":"2875_CR36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00345-009-0377-1","volume":"27","author":"Barlow","year":"2009","unstructured":"Barlow LJ, McKiernan JM, Benson MC (2009) The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 27:331\u2013335","journal-title":"World J Urol"},{"key":"2875_CR37","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.ju.0000146274.85012.e1","volume":"173","author":"Van","year":"2005","unstructured":"Van der Heijden AG, Verhaegh G, Witjes JA et al (2005) Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol 173:1375\u20131380","journal-title":"J Urol"},{"key":"2875_CR38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.0306-5251.2001.01449.x","volume":"52","author":"Paroni","year":"2001","unstructured":"Paroni R, Salonia A, Lev A et al (2001) Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 52:273\u2013278","journal-title":"Br J Clin Pharmacol"},{"key":"2875_CR39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eururo.2004.01.019","volume":"46","author":"Van","year":"2004","unstructured":"Van der Heijden AG, Kiemeney LA, Gofrit ON et al (2004) Preliminary European results of local microwave chemotherapy for the treatment in intermediate or high-risk superficial transirional cell carcinoma of the bladder. Eur Urol 46:65\u201372","journal-title":"Eur Urol"},{"key":"2875_CR40","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","volume":"27","author":"Witjes","year":"2009","unstructured":"Witjes JA, Hendricksen K, Nativ O et al (2009) Intravesical hyperthermia and mitomycin C for carcinoma in situ of the urinary bladder: expirience of the European Synergo working party. World J Urol 27:319\u2013324","journal-title":"World J Urol"},{"key":"2875_CR41","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","volume":"182","author":"Nativ","year":"2009","unstructured":"Nativ O, Witjes JA, Leibovitch I et al (2009) Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol 182:1313\u20131317","journal-title":"J Urol"},{"key":"2875_CR42","unstructured":"National Cancer Institute (NCI) (2010) HYMN: a randomized controlled phase III trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette-Guerin or standard therapy in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance bacillus Calmette-Guerin therapy. NCI, Bethesda, MD, USA"},{"key":"2875_CR43","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0090-4295(97)00625-0","volume":"51","author":"Brausi","year":"1998","unstructured":"Brausi M, Campo B, Pizzocaro G et al (1998) Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Urology 51:506\u2013509","journal-title":"Urology"},{"key":"2875_CR44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00345-009-0389-x","volume":"27","author":"Di","year":"2009","unstructured":"Di Stasi SM, Riedl C (2009) Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. World J Urol 27:325\u2013330","journal-title":"World J Urol"},{"key":"2875_CR45","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","volume":"12","author":"Di","year":"2011","unstructured":"Di Stasi SM, Vespasiani et al (2011) Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomized controlled trial. Lancet Oncol 12:871\u2013879","journal-title":"Lancet Oncol"},{"key":"2875_CR46","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","volume":"170","author":"Di","year":"2003","unstructured":"Di Stasi SM, Giannantoni A, Stephen RL et al (2003) Intravesical electromotive drug administration of mitomycin C versus passive transport of mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 170:777","journal-title":"J Urol"},{"key":"2875_CR47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","volume":"7","author":"Di","year":"2006","unstructured":"Di Stasi SM, Giannantoni A, Stephen RL et al (2006) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomized controlled trial. Lancet Oncol 7:43\u201351","journal-title":"Lancet Oncol"},{"key":"2875_CR48","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","volume":"44","author":"Meijden","year":"2003","unstructured":"Meijden AP van der, Sylvester RJ, Oosterlinck W et al (2003) Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44:429\u2013434","journal-title":"Eur Urol"},{"key":"2875_CR49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"B\u00f6hle","year":"2003","unstructured":"B\u00f6hle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90\u201395","journal-title":"J Urol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-012-2875-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-012-2875-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-012-2875-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T15:37:16Z","timestamp":1561736236000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-012-2875-9"}},"subtitle":["Lokale Therapieoptionen?"],"short-title":[],"issued":{"date-parts":[[2012,5,13]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["2875"],"URL":"https:\/\/doi.org\/10.1007\/s00120-012-2875-9","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,13]]}}}